Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Sight-saving eye injection for wet macular degeneration. | Cuts off a tumour's blood supply. |
| Body system | Eyes | Cancer |
| Drug class | Anti-VEGF injections | Targeted antibodies |
| Supply | Prescription only | Prescription only |
| Main uses | Wet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusion | Bowel cancer, Lung cancer, Ovarian and cervical cancer, Glioblastoma, Wet macular degeneration (off-label eye injections) |
| How it works | Blocks the signal that grows leaky vessels at the back of the eye. | Stops tumours growing the blood vessels they need. |
| Starts working | — | — |
| Half-life | — | About 20 days |
| Typical adult dose | 2 mg monthly for 3 months, then every 8–16 weeks (8 mg high-dose can extend further). | 5–15 mg/kg IV every 2–3 weeks depending on cancer. |
| Forms | Intravitreal injection | IV infusion, Intravitreal injection (ophthalmic forms in some countries) |
| Common side effects | Eye redness, Floaters, Eye pain | High blood pressure, Protein in urine, Nosebleeds, Tiredness |
| Serious side effects | Eye infection (endophthalmitis), Retinal detachment, Raised eye pressure | Bowel perforation, Bleeding, Poor wound healing, Clots |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Usually avoidedNot recommended. | Usually avoidedContraception for 6 months after. |
| Breastfeeding | — | — |
| In use since | 2011 | 2004 |
| Brand names | United States: Eylea, Eylea HDUnited Kingdom: EyleaIndia: Eylea | United States: Avastin, Mvasi, ZirabevUnited Kingdom: Avastin, AlymsysIndia: Bevatas, Abevmy |
| Legal status | — | — |
| ATC code | S01LA05 | L01FG01 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker